Antibody Binding Sites

Subscribe to Selected New Research on Antibody Binding Sites

54 relevant articles (1 outcomes, 7 trials/studies) found for this Bio-Agent

Description: Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of FAB FRAGMENTS.

Also Known As:

Binding Sites, Antibody; Antibody Binding Site; Binding Site, Antibody; Paratope; Paratopes

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lee, Wonbae: 1 article (01/2008)
2.	Park, Hun Hee: 1 article (01/2008)
3.	Choi, Bo Yeon: 1 article (01/2008)
4.	Han, Kyungja: 1 article (01/2008)
5.	Kahng, Jimin: 1 article (01/2008)
6.	Bhol, K C: 1 article (02/2001)
7.	Razzaque Ahmed, A: 1 article (02/2001)
8.	Kumari, S: 1 article (02/2001)
9.	Letko, E: 1 article (02/2001)
10.	Foster, C S: 1 article (02/2001)

Related Diseases

1.	Disease Progression 09/01/2007 - "The identification of an effective antibody-binding site, targeted by a functional neutralizing antibody, and findings confirming that the Gag-specific responses are effective in protecting against disease progression are major advances in this field. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 08/01/1979 - "The application of the method for studies on the generation of immunoresistant tumor cell variants and on the relationship between antibody-binding sites and rejection target sites is discussed." 02/01/1989 - "As reported previously, 3A4 is a paratope-specific anti-idiotypic mAb and induces cellular and humoral anti-tumor-associated Ag (TAA) responses. " 02/01/1985 - "The number of antibody-binding sites per cell on the tumor cell surface was significantly higher for tumoricidal MAb as compared to unreactive MAb. On the other hand, the percentage of tumor cells binding the MAb and the binding affinity to these cells were the same for the two groups of MAb. Also, tumoricidal and nontumoricidal MAb bound with similar affinity and antibody density to Fc receptors on macrophages. " 02/01/1987 - "Finally, using iodine-125 labeled preparations of purified Lym-1 and Lym-2, we have determined that both reagents have a relatively large number of antibody binding sites per tumor cell and increased avidity for lymphoma cells when compared to normal and reactive lymph node B-cells.(ABSTRACT TRUNCATED AT 400 WORDS)" 09/01/2003 - "Novel therapeutic approaches aimed at inhibiting increased EGFR-TK activity include antibodies that block the extracellular ligand-binding site, antibody or ligand fusion proteins that specifically target toxins to the tumor cells, or small-molecule TK inhibitors (TKIs) that act intracellularly to block downstream signal transduction from EGFR. " Order ALL the reference details at left...
3.	Infection 07/01/2000 - "In addition to being highly expressed (approximately 1000-7000 STRL33 ABS [antibody binding sites]) on specific subsets of natural killer cells (CD3(-)/CD16(-/low)/CD56(+) and CD3(-)/CD16(low)/CD56(-)) and CD19(+) B lymphocytes (approximately 300-5000 STRL33 ABS), STRL33 was expressed at levels sufficient to support virus infection on freshly isolated, truly naive CD4(+)/CD45RA(+)/CD62L(+) cells (6000-11 000 ABS). " 04/01/1989 - "These results indicate that active immunization with a fusion protein containing the cross-reactive CTL epitope protects mice from influenza infection by inducing CTL against influenza A H1 and H2 subtype virus strains, which markedly vary in their antibody binding sites on the HA1. " 12/01/2008 - "This study provides insights on the paratope-epitope interaction and can be used to identify compounds with comparable properties as the paratope leading to future development of drugs and vaccines for WSSV infection." 09/01/1993 - "The observations indicate that the non-paratope domains of antiviral antibodies can influence their function as neutralizing or enhancing for infection." 11/01/2002 - "Variants in the amino acid composition of the primary antibody-binding site of hepatitis B surface antigen (HBsAg) have been identified in a number of populations with chronic hepatitis B virus (HBV) infection. " Order ALL the reference details at left...
4.	Typhoid Fever (Typhoid) 11/01/2003 - "Binding of MAb ATVi to the mimotopes was specifically blocked by ViCPS, indicating that they interact with the same binding site (paratope) of the MAb. Data and reagents generated in this study have important implications for the development of peptide-base diagnostic tests and peptide vaccines and may also provide a better understanding of the pathogenesis of typhoid fever." Order ALL the reference details at left...
5.	Poisoning 07/20/1993 - "A partially protective effect of the antibodies against amanitin toxicity in vitro in Chang cells was evident at a molar ratio of antibody binding sites to alpha-amanitin of 4:1. Together with reported studies in vivo, these investigations indicate the potential of immunotherapy for amanitin poisoning." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Anti-Idiotypic Antibodies
3.	Indicators and Reagents (Reagents)
4.	Alpha-Amanitin
5.	Subunit Vaccines
6.	Vaccines
7.	bovine (152-168) serum albumin (ABBOS)
8.	Antigens
9.	Glycoproteins (Glycoprotein)
10.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Immunotherapy
2.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Disease Progression

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 532 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>